Lyra Therapeutics (LYRA) Net Margin (2021 - 2025)
Lyra Therapeutics (LYRA) posted Net Margin of 12428.57% for Q4 2025, up 48.08% on a QoQ basis from 23936.0% in Q3 2025, and down 1657881.0% year-over-year from N/an in Q4 2024.
Powered by 
Analysis
Lyra Therapeutics (LYRA) Net Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics has reported Net Margin for 5 years, with the latest figure at 12428.57% in Q4 2025.
- On a quarterly basis, Net Margin fell 1657881.0% year-over-year to 12428.57% in Q4 2025; TTM through Dec 2025 was 5738.19%, a 92841.0% decrease from a year earlier, with the FY2025 full-year figure at 5738.19%, down 92841.0% from the prior year.
- Net Margin was 12428.57% for Q4 2025 at Lyra Therapeutics, up from 23936.0% in the prior quarter.
- The five-year high for Net Margin was 4150.24% in Q4 2024, with the low at 129290.91% in Q4 2022.
- Average Net Margin over 5 years is 16811.86%, with a median of 4445.4% recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Net Margin tumbled 12426619 bps in 2022, then soared 11891009 bps in 2023.
- Over 5 years, Net Margin stood at 5024.72% in 2021, then plunged by 2473 bps to 129290.91% in 2022, then surged by 92 bps to 10380.82% in 2023, then soared by 140 bps to 4150.24% in 2024, then tumbled by 399 bps to 12428.57% in 2025.
- The last three Net Margin figures came in at 12428.57% (Q4 2025), 23936.0% (Q3 2025), and 4063.93% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 3.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,152.98% |
| 10 | Lyra Therapeutics | 354,976.41 | 354,976.41 | - | -12,428.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -12,428.57% |
| Sep 30, 2025 | -23,936.00% |
| Jun 30, 2025 | -4,063.93% |
| Mar 31, 2025 | -4,670.49% |
| Dec 31, 2024 | 4,150.24% |
| Sep 30, 2024 | -6,088.72% |
| Jun 30, 2024 | -8,048.66% |
| Mar 31, 2024 | -4,220.30% |
| Dec 31, 2023 | -10,380.82% |
| Sep 30, 2023 | -2,877.02% |
| Jun 30, 2023 | -3,410.04% |
| Mar 31, 2023 | -3,964.63% |
| Dec 31, 2022 | -129,290.91% |
| Sep 30, 2022 | -4,113.09% |
| Jun 30, 2022 | -2,736.38% |
| Mar 31, 2022 | -2,545.09% |
| Dec 31, 2021 | -5,024.72% |
| Sep 30, 2021 | -78,964.29% |